Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Up 41.2% in December

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 80,987 shares, an increase of 41.2% from the November 30th total of 57,363 shares. Currently, 2.1% of the shares of the company are short sold. Based on an average daily volume of 193,362 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 193,362 shares, the days-to-cover ratio is currently 0.4 days. Currently, 2.1% of the shares of the company are short sold.

Avalon GloboCare Stock Down 6.0%

Shares of Avalon GloboCare stock opened at $1.26 on Wednesday. The company has a market capitalization of $5.36 million, a price-to-earnings ratio of -0.36 and a beta of -0.11. The stock’s 50-day simple moving average is $1.61 and its 200-day simple moving average is $2.15. Avalon GloboCare has a 52 week low of $0.88 and a 52 week high of $11.66.

Avalon GloboCare (NASDAQ:ALBT) last issued its earnings results on Friday, November 14th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company had revenue of $0.35 million during the quarter.

Wall Street Analyst Weigh In

ALBT has been the subject of several research analyst reports. Wall Street Zen downgraded Avalon GloboCare to a “strong sell” rating in a report on Saturday, September 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avalon GloboCare in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.